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Objective: To calculate direct cost per asthma exacerbation at tertiary healthcare centers
across Turkey.
Methods: A total of 294 persistent asthma patients (mean age: 50.4  15.1 years) were
included in this retrospective study upon admission with an acute asthma attack. Direct costs
including drug treatment, non-drug treatment, healthcare resource utilization, emergency
care, tests and consultations were calculated per asthma attack in relation to asthma attack
severity.
Results: The asthma attack was moderate in 57.5% of the patients. Direct cost was V214.9
(95% CI: 183.9; 245.8) per attack. The cost of severe attack V308.2 (95% CI: 258.2; 358.2)]
was significantly higher than moderate [V172.6 (95% CI: 155.1; 190.2)] and mild [V128.6
(95% CI: 102.6; 154.7) attacks. It was also significantly higher for inpatient follow-up
[V257.7 (95% CI: 220.4; 295)] vs. outpatient follow-up [V54.5 (95% CI: 47; 62; p< 0.001)]
and uncontrolled asthma [V288.2 (95% CI: 216.7; 359.6)] vs. controlled [V128.9 (95% CI:
92.1; 165.8); p< 0.01] asthma.
Conclusion: Health policies targeting achievement of better asthma control and lower disease
severity during the stable periods of the disease as well as appropriate hospitalization of
patients and rational prescribing of drugs will play crucial role in the reduction of economic
burden of asthma for the patient and the society.
ª 2010 Elsevier Ltd. All rights reserved.2 595 65 81; fax: þ90 312 319 00 46.
dicine.ankara.edu.tr (S. Bavbek).
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Economic burden of asthma has been a current topic of
interest across several countries due to worldwide increase
in the prevalence of the disease comparable to the burden
of diabetes and hypertension.1,2 Although recommenda-
tions for asthma control are included in the international
guidelines, many patients continue to suffer sub-optimal
control of symptoms and experience exacerbations1
requiring medical intervention that affect the quality of
life for the patient and the family3 imposing a considerable
strain on the healthcare budget.4 Therefore, having 300
million sufferers worldwide with additional 100 million
people estimated to be affected by 2025,5 asthma also
deserves to be included in investigations concerning
economic implications of diseases with a high prevalence.6
Accordingly, several cost-of-illness (studies examining the
economic impact of asthma in the society) have been per-
formed in many countries leading to annual cost of asthma
ranging from $10.7 billion to V 74 billion per year in total
and $300 to 1300 per patient.7e9
Almost all indirect costs and 1/3 of direct costs of
asthma were documented to be related to exacerbations
and poor control of the disease10 with more than threefold
increase in average cost of managing a patient documented
in case of asthma exacerbation.2
Direct healthcare costs such as medication, medical
bills, clinical visits and hospitalization(s), and indirect costs
such as loss of productivity have been shown to rise
dramatically for more persistent and severe disease.11,12
Lacking sufficient data based on health system records,
the number of patients diagnosed with asthma in Turkey
was estimated to be 3e4 million13 and the prevalence of
asthma in Turkey was documented to be 7.4% according to
Global Initiative for Asthma (GINA) e Global Burden of
Asthma Report.14 Furthermore, a low level of asthma
control in urban Turkish population was reported by the
recently published AIRET survey despite the use of the
national asthma management guideline in the clinical
practice since 1995.15 Likewise, asthma control was also
documented to be inadequate at the tertiary level while
overall control was better than past reports.16 Patients with
severe asthma account for a substantial portion of health-
care costs despite well documented low prevalence of
severe form in overall asthmatic population.17e19 The
direct cost of these patients was reported to be two and
four times higher than that of moderate and mild asthma
patients, respectively20 resulting from high risk of exacer-
bations, hospitalizations, and death associated with poor
control of the disease despite the use of high dose inhaled
or oral steroids.18
While mean annual direct medical costs of asthma were
reported as $1465.7 111.8 per capita with the medica-
tion cost being the major element (81%) of the total direct
cost in a recent study conducted in a single tertiary center
in Turkey,20 national data concerning cost per asthma
attack across Turkey is lacking. Therefore, the present
study was designed to estimate the direct medical cost
per asthma exacerbation to provide country specific data
in relation to attack severity and level of disease control
in Turkey.Methods
Study population
This national, multi-center study involving 294 patients with
persistent asthma admitted to healthcare service upon
symptoms of acute exacerbation was conducted retrospec-
tively, concerning past 24 months at 15 different tertiary
healthcare centers across Turkey. Tertiary healthcare centers
for chest diseaseswere selectedby theProject Advisory Board
of the study according to the geographical distribution of
specialists and family physicians in Turkey. In accordancewith
the real life setting of the study based on routine clinical
practice, inclusion criteria were kept at minimum. Being18
years of age, having diagnosis of persistent asthma and being
admitted to the hospital with symptoms of acute asthma
attackwithin the past 24monthswere the inclusion criteria of
the study. In fact, regardless of theattack count/year, the last
attack of patientwith an interval of at least 3months from the
prior onewithin24monthswas evaluated in thepresent study.
Hence data on just one single asthma attack per patient were
collected to calculate the cost per the most recent attack in
eachpatient.Therefore,while it ispossible toencountermore
than one attack in the same patient within the 24-month
window, the last and themost recent onewas selected for the
cost analysis.
Exclusion criteria were composed of diagnosis of asthma
attack during patient’s routine visit and determination of
less than 3 months interval between subsequent admissions
of the same patient related to acute asthma exacerbation
within the screening period. The selected time interval of
at least 3 months between consecutive attacks was based
on to be able to calculate the cost per the most recent
attack excluding the likelihood of certain complications
related to prior attack that may interfere with the cost
calculations such as carry over effects.
The study was conducted in accordance with Interna-
tional Conference on Harmonisation (ICH) e Good Clinical
Practice (GCP) guideline and local regulations. Data were
collected via a standardized form including items on
patient demographics and clinical data concerning severity
of the attack, medications and tests applied for the acute
attack. Direct cost of acute asthma attack including
treatment, healthcare resources utilization, and test and
consultation items was evaluated in relation to attack
severity, type of follow-up (outpatient vs. inpatient) and
level of disease control.
Classification according to attack severity and
asthma control level
Participating clinicians were responsible for assessing the
severity of attack based on Global Initiative for Asthma
(GINA) guideline.14 Asthma control level was classified as
controlled, partly controlled and uncontrolled based on the
time prior to the attack and asthma attack severity was
categorized into four groups as mild, moderate, severe and
life-threatening according to the same guideline.14 In this
regard, patients in the study population are amongst the
follow-up patients of the study clinics. Most of them were
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cerning pre-attack asthma control and severity.
Cost calculations
Direct medical costs were calculated including the associated
cost items composed of treatment, healthcare resources
utilization, and diagnostic test and consultation costs. For
drugs, retail prices from the updated price list and updated
institution discount list of Social Security Institution (SSI) for
2008 were taken into account in calculation of the unit costs.
Costs related to non-pharmacological treatments and tests
were calculated considering the Health Implementation
Notification by SSI. Hospitalization and consultation costs
were calculated using unit prices also based on the same SSI
notification. Salaries and labor force of healthcare staff giving
service to patients with asthma was provided from the
Healthcare Organization Questionnaire composed of Staff
Inventory Form and Information Form on the Labor Force
Spent during an Asthma Attack filled for each study center.
Neither direct non-medical costs of different origin (e.g.
transfers of patient and caregivers for examinations and/or
hospitalization, home care, etc.) nor indirect costs (loss of
productivity occurring as a result of a patient’s inability to
work) were included. The costs in Turkish Lira (TL) are
converted to V o (V) by using the average exchange rate of
the years 2008 and 2009 which is V1Z 2.02315 TL.
Statistical analysis
Statistical analysis was made using computer software (SPSS
version 13.0, SPSS Inc. Chicago, IL, USA). Student’s-test,
ANOVA and post hoc Tukey test were used in comparison of
clinical parameters in terms of average direct cost items.
Medical expenses related to diagnosis, treatment, follow-up
and management of acute asthma attack was the main
parameter of the study. Cost model was based on the
following equation: “CostZ
P
(Frequency; %) (Unit price;
TL)”. As central tendency measurement, both mean and
median were calculated for all cost items. Although it is
known that cost figures show non-normal distribution, mean
costwas used for thewhole group as it represents the disease
burden better. Standard deviation and IQR values were
calculated as dispersion measure, and 95% confidence
intervals (CI) were also calculated. Data were expressed as
“mean  standard deviation (SD)”, percent (%) and median
(minemax) where appropriate. p< 0.05 was considered
statistically significant.
Since life-threatening asthma episodes were repre-
sented by only 4 cases, analysis for this group was confined
to descriptive statistics. Therefore, all of the comparisons
considering severity of the attack included mild, moderate
and severe attacks.
Results
Demographic and clinical data
Demographic and basic clinical features of the study pop-
ulation are presented in Table 1. Majority of the patientswerefemales (80.3%) and the overall mean age was 50.4 15.1
(18e90) years.Only13.9%of themhadcontrolledasthmaprior
to the attack. First admission was determined to be to the
emergency department only by 32% of the patients. The
asthmaattackwasmoderate inmore thanhalf (57.5%),mild in
18.7%, severe in 22.4% and life-threatening in 1.4% of the
patients. Hospitalization ratio was determined to be 78.9%.
Medications and tests applied for the acute attack
treatment and follow-up
Parenteral steroids in 72% of the patients and oral steroids
in 29% were the anti-inflammatory drugs used in the
treatment of asthma attack. Bronchodilators were deter-
mined to be SABAs in 53% and short acting anti-cholinergic
plus salbutamol combination in 42% of the patients.
Reflecting the way of bronchodilator application, nebulizer
was the most commonly used treatment tool (91.8%).
Spirometry and chest X-ray were the most frequent tests
(85.4% for both) used during attack followed by oxygen
saturation measurement (62.6%). The other tests used during
the attack were as follows: ECG (60.7%), arterial blood gas
sampling (55.5%), complete blood count (36.9%), blood
biochemistry (25.2%), peak expiratory flow (PEF; 5.5%), and
others (microbiological tests, thorax CT, echocardiography).
Cost analysis
Total direct cost items in relation to severity of the
asthma attack
Average total direct cost per asthma exacerbation was
V214.9 (95% CI: 183.9; 245.8). Treatment cost (55.6%) was
the most predominant direct cost item followed by
healthcare resources utilization (24.7%), diagnostic tests
(19.2%) and consultation (0.5%) costs (Table 2). Total direct
cost per attack was significantly higher in patients with
severe asthma attacks when compared to moderate and
mild attacks (p< 0.001 for each; Fig. 1).
Treatment cost item in subgroups of attack severity
Treatment cost item per attack was significantly higher in
the severe attack group when compared to moderate and
mild attacks (p< 0.001 for each; Fig. 1). Among treatment
cost items, drug treatment cost, asthma medication cost
and non-drug treatment cost were significantly higher in
the severe attack group when compared to moderate and
mild attack groups (p< 0.01 for each). Average cost of
asthma medication was V23.9 (95% CI: 18.53; 29.30) in mild
attacks; V32.1 (95% CI: 27.55; 36.55) in moderate attacks
and V43.3 (95% CI: 35.78; 50.89) in severe attacks. Non-
drug treatment costs were V32.6 (95% CI: 25.21; 39.92);
V42.6 (95% CI: 36.31; 48.88) and V101.1 (95% CI: 80.95;
121.26) in mild, moderate and severe attacks, respectively.
As expected, other drug treatment (drugs other than
asthma medication) cost was not significantly different
between groups with different attack severity.
Healthcare resources utilization and cost of diagnostic
tests in subgroups of attack severity
Overall healthcare resources utilization cost was signifi-
cantly higher in the severe attack group when compared to
Table 1 Demographic and basic clinical features of
patients with asthma attack.
Mean ± SD
Age (years) Overall 50.4 15.1
Female 52.0 14.8
Male 43.7 14.4
n (%)
Gender Female/Male 236/58 (80.3/19.7)
Pre-attack
asthma control
Controlled 41 (13.9)
Partly controlled 138 (46.9)
Uncontrolled 115 (39.1)
Admission to Emergency
department
94 (32.0)
Outpatient clinics 200 (68.0)
Attack severity Mild 55 (18.7)
Moderate 169 (57.5)
Severe 66 (22.4)
Life threatening 4 (1.4)
Outpatient follow-up 62 (21.0)
Inpatient follow-up 232 (78.9)
544 S. Bavbek et al.moderate and mild attack groups (p< 0.05 for each; Fig. 1).
Inpatient follow-up cost, diagnostic test cost and consul-
tation cost were significantly higher in the severe attack
group when compared to moderate and mild attack groups
(p< 0.05 for each). Average cost of inpatient follow-up was
V26.5 (95% CI: 18.44; 34.46) in mild attacks; V43.02 (95%
CI:36.76; 49.28) in moderate attacks; and V 67.3 (95% CI:
55.65; 78.84) in severe attacks. Diagnostic test costs were
V26.5 (95% CI: 21.37; 31.71) in mild attack while it was
V34.5 (95% CI: 30.55; 38.51) in moderate and V59.7 (95%Table 2 Average direct costs of asthma exacerbation (V/attack
tests and consultation items (nZ 294).
Average direct cost (V
Mean SD
Total 214.85 268.38
Treatment item
Overall 119.54 183.80
Drug treatment
Overall 62.99 144.36
Asthma medication 34.47 31.94
Other 28.52 127.02
Non-drug treatment 56.54 62.41
Healthcare resources utilization item
Overall 53.01 61.1
Outpatient follow-up 1.69 3.17
In patient follow-up 49.47 62.18
Emergency department 1.85 3.62
Tests item
Overall 41.33 44.53
Consultation item
Overall 0.98 2.28
SD: Standard deviation; IQR: Interquartile range; CI: Confidence interCI: 48.5; 70.6) in severe attacks. Consultation costs were
V0.22 (95% CI: 0.00; 0.43); V0.8 (95% CI:0.46; 1.12) and
V1.8 (95% CI:1.13; 2.46) in mild, moderate and severe
attacks, respectively. On the other hand, outpatient
follow-up cost in the mild attack [V2.78 (95% CI:1.78; 3.79);
p< 0.05] was significantly higher when compared to severe
attack [V1.03(95% CI:1.78; 3.79) and emergency depart-
ment cost in the moderate attack [V1.5 (95% CI:0.98; 1.95)]
was lower than severe attack [V2.75 (95% CI:1.59; 39);
p< 0.05].
Direct cost of outpatient vs. inpatient follow-up
When outpatient and inpatient follow-up costs were
compared in terms of total direct cost and its items including
treatment, healthcare resources utilization, diagnostic test
and consultation costs, it was found that all were signifi-
cantly higher in case of inpatient follow-up (p< 0.001 for
each; Table 3).
Direct cost with respect to prior asthma control level and
use of inhaled steroids
Overall direct cost and healthcare resource utilization cost
were found to be higher in patientswith uncontrolled asthma
compared to those with partly controlled and controlled
disease (p< 0.05; for each; Fig. 2). When analyzed sepa-
rately, inpatient follow-up cost was found to be higher in
patients with uncontrolled asthma [V65.0 (95% CI: 49.7;
80.3)] compared to patients with partly controlled [V42.9
(95% CI:35.7; 50.2); p< 0.05] and controlled disease [V28.0
(95% CI: 18.0; 38.0); p< 0.01]. On the contrary, outpatient
follow-up cost [V3.3 (95%CI: 2.1; 4.5)]was found tobehigher
in patients with controlled asthma compared with partial
[V1.8 (95%CI: 1.2; 2.3);p< 0.05] andpoor [V1.0 (95%CI: 0.5;
1.5); p< 0.001] asthma control.) with respect to treatment, healthcare resources utilization,
/attack)
Median (IQR) 95% CI
159.46 (175.74) 183.93; 245.77
78.12 (106.71) 98.44; 140.63
38.73 (54.60) 46.43; 79.57
26.05 (37.71) 30.81; 38.14
1.62 (19.14) 13.94; 43.10
34.45 (55.04) 49.38; 63.70
44.49 (59.22) 45.99; 60.02
0.00 (0.00) 1.32; 2.05
37.7 (59.32) 42.33; 56.61
0.00 (0.00) 1.43; 2.26
31.09 (28.8) 36.22; 46.44
0.00 (0.00) 0.72; 1.24
val.
0100
200
300
400
500
mild
moderate
severe 
)
RUE(
kc
att
a
a
mhts
af
ots
octc
erid
eg
arevA
*
**
Total
direct cost
Treatment
item
Healthcare
resource item
*
**
**
**+
attack severity 
Figure 1 Average direct cost (mean  SD; V) of asthma
exacerbation including treatment and healthcare resource
utilization items with respect to severity of asthma attack.
)p< 0.05 and ))p< 0.001 compared to cost in severe asthma
attack. þp< 0.05 compared to cost in moderate asthma
attack.
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treatment cost was found to be higher in patients with
uncontrolled asthma compared to patients with partly
controlled (p< 0.05) and controlled (p< 0.01) disease
(Fig. 2). In detail, asthma medication cost was higher in the
uncontrolled asthma group [V39.4 (95% CI: 32.8; 46.0)] vs.
controlled [V24.5 (95% CI: 16.8; 32.2); p< 0.05]; and non-
drug treatment cost was higher in the uncontrolled asthma
[V85.1 (95% CI: 69.9; 100.2)] compared with partly
controlled [V41.6 (95% CI: 35.3; 47.9)] and controlled
[V26.8 (95% CI: 20.0; 33.6)] asthma (p< 0.001 for each).
Costs related to diagnostic tests and consultations were
also higher in the uncontrolled asthma compared with
partly controlled and controlled forms of the disease
(p< 0.001; for each; Fig. 2).
Interestingly, when analyzed according to ICS use prior
to the attack, cost of emergency care was detected to be
higher in ICS positive patients [V2.04 (95% CI:1.5; 2.5)]
when compared to lack of steroid administration [V1.02
(95% CI:0.2; 1.8); p< 0.05]. Similarly, significantly higher
costs were found regarding diagnostic tests [V44.6 (95%
CI:38.0; 51.2) vs. V 31.24 (95% CI:26.2; 39.3); p< 0.05] and
consultations [V1.14 (95% CI:0.8; 1.4) vs. V0.52 (95% CI:0.2;
0.9); p< 0.05] in patients received ICS.
Discussion
In this study, average direct cost of asthma an attack was
found to be V214.9 per asthma attack across Turkey. Indi-
cating the burden of severe attack on health economics,
direct cost was calculated to be V128.6 for mild attack,
V172.6 for moderate attack, V308.2 for severe attack and
V1645 for life-threatening asthma attack. There area limited number of multi-center studies concerning cost of
asthma attack in the literature. Representing one of them,
COAX study was conducted with more than 2000 subjects
from fifteen countries and reported the cost of asthma
attack to be V445 in primary and V1349 in secondary care
centers with the cost of V737 for mild attack, while V881
and V1074 for moderate and severe attacks.10 Notably,
there are no studies concerning cost per asthma attack in
primary and secondary care in our country. Therefore,
while cost per asthma attack in primary and secondary care
in other countries seems immensely higher when compared
to cost per attack in tertiary care across Turkey, the data
from different countries may not be comparable due to
significant differences between countries in terms of health
policies as well as the disease management.
According to our findings, as the major item of direct
cost per attack, treatment cost (55.6%) was calculated to
be V70.7 for mild attack, V90.9 for moderate attack,
V175.5 for severe asthma attack. Our data concerning the
relation of higher asthma medication cost to the severe
asthma attack are in line with the past studies from
Sweden, the Netherlands, the United States and France
signifying the drugs as the key cost driver among the direct
costs both in the different age groups and also among the
different severity grades of asthma.6,8,21,22 Besides drug
costs, non-drug treatment costs were also significantly
higher in the severe attack group when compared to
moderate and mild attack groups in the present study.
Moreover, significant proportion of overall treatment cost
in our study was composed of non-drug treatment item
which was determined to exceed drug cost in moderate and
severe attack patients. Drug cost and hospitalization were
also documented to be main items responsible for the
burden of asthma on health economics in a past study in
Turkish asthmatic patients in which significant difference in
the annual cost of outpatient (139.76 TL) and inpatient
follow-up (506.91 TL) of asthma was emphasized.20
Asthma attacks that were associated with hospitalization
were reported to account for 90% of the total costs of
attacks.23 Accordingly, all direct cost items were signifi-
cantly higher among inpatient population when compared to
outpatient follow-up for asthma in our study. Based onmajor
contribution of inpatient follow-up to healthcare resource
utilization cost, appropriate hospitalization seems to have
a significant role in the direct cost of asthma attack. Unfor-
tunately, detection of hospitalization in almost 80% of our
patients is highly suggestive of unnecessary and inappro-
priate hospitalization since asthma attack was mild to
moderate inmore than75%of them.As amatter of fact, since
asthma prior to acute attack was determined to be
controlled and partially controlled in as much as 75% of
patients in the outpatient follow-up group, higher outpatient
costs associated with good asthma control compared with
partial or poor control seem to reflect how patients are
managed rather than a real difference in healthcare costs.
According to our findings, higher attack severity was
significantly associated with increase in direct medical cost
including drug and non-drug treatment, healthcare
resources utilization and tests cost items. In fact, similarity
between mild to moderate attacks in terms of cost item
seems to indicate the inevitable burden of severe asthma
attacks on health economics which may be reduced by
Table 3 Comparison of outpatient (nZ 62) vs. inpatient (nZ 232) follow-up in terms of total direct cost (V/attack),
treatment, healthcare resources utilization, diagnostic tests and consultation cost items.
Average direct cost (V/attack)
Mean SD Median (IQR) 95% CI
Total direct cost
Outpatient 54.47 29.46** 44.60(25.18) 46.99; 61.95
Inpatient 257.71 288.21 193.10(166.17) 220.43; 294.99
Treatment cost
Overall
Outpatient 31.98 24.39** 22.71(23.95) 25.79; 38.18
Inpatient 142.94 200.20 96.01(109.57) 117.04; 168.83
Drug treatment
Overall
Outpatient 18.79 24.35** 8.57(18.04) 12.61; 24.97
Inpatient 74.81 160.04 43.43(57.42) 54.11; 95.51
Asthma medication
Outpatient 12.51 15.43** 7.09(10.30) 8.59; 16.43
Inpatient 40.35 32.67 34.09(35.07) 36.12; 44.57
Other
Outpatient 6.28 17.18* 0.07(0.68) 1.92; 10.65
Inpatient 34.47 142.19 3.35(22.42) 16.08; 52.86
Non-drug treatment
Outpatient 13.19 6.74* 12.36(5.33) 11.48; 14.90
Inpatient 68.13 65.49 43.01(58.38) 59.65; 76.59
Heathcare resources utilization
Overall
Outpatient 7.60 0.09* 7.66(0.08) 7.58; 7.63
Inpatient 65.14 63.52 51.90 (43.02) 56.92; 73.36
Outpatient follow-up
Outpatient 5.03 3.63* 7.54 (7.66) 4.11; 5.95
Inpatient 0.79 2.33 0.00 (0.00) 0.49; 1.09
Inpatient follow-up
Outpatient e e e
Inpatient 62.69 63.82 48.81 (43.10) 54.44; 70.95
Emergency department
Outpatient 2.58 3.63 0.00 (7.58) 1.66; 3.50
Inpatient 1.65 3.61 0.00 (0.00) 1.19; 2.12
Diagnostic tests
Outpatient 14.79 7.95* 15.89(4.24) 12.77; 16.81
Inpatient 48.42 47.53 35.99(31.00) 42.27; 54.57
Consultation
Outpatient 0.09 0.53* 0.00 (0.00) 0.04; 0.23
Inpatient 1.22 2.50 0.00 (2.97) 0.89; 1.54
SD: Standard deviation; IQR: Interquartile range; CI: Confidence interval. *p< 0.05; *p< 0.01 and **p< 0.001 compared to inpatient
cost.
546 S. Bavbek et al.earlier identification of patients at highest risk for adverse
outcomes24 which is potentially a cost-effective measure.25
In this context, while represented by only 4 patients
limiting to draw exact conclusions about, life-threatening
asthma attack was associated with at least 10 times
increase in cost items. In a similar fashion, 4e9 times
increase in cost items were also evident for hospitalization
compared with outpatient therapy according to our find-
ings. Higher cost related to severe attacks in our study
conducted at tertiary healthcare centers seems to be
relevant with respect to documented linear relationbetween cost and the severity of attack managed in the
secondary care.1,2 Likewise, in a recent local study evalu-
ating cost of asthma attack in a university hospital in
Turkey, severe attack was documented to be related to
increased cost.26
Despite universal agreement on beneficial effects of
steroids in the management of acute asthma exacerbations,
there appears to be little consensus regarding the route and
dose for initial emergency department administration,
outpatient regimen, and duration of outpatient steroid
therapy.14 Accordingly, despite suggested to reduce the
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Figure 2 Average direct cost (mean  SD; V) of asthma
attack in patients with controlled (n Z 41), partly controlled
(nZ 138) and uncontrolled (115) asthma. )p< 0.05 and
))p< 0.01; compared to uncontrolled asthma.
Direct cost per asthma exacerbation in Turkey 547likelihood of hospitalization for asthma attacks, and accident
and emergency visits especially if combined with long-acting
inhaled bronchodilators,1,27 use of inhaled corticosteroids
(ICS) was shown to be associated with higher costs related to
emergency care, tests and consultations in our patients in
relation to associated disease severity. Based on the higher
severity of the attack among our ICS positive patients leading
higher emergency costs than those without ICS who were
determined to havemuchmilder attacks, ICS positivity seems
to be an indicator of more severe disease. In this regard, use
of inhaled corticosteroid was reported to be 20e30% among
asthma patients in the AIRET study with predominance of
severe asthma, as well as in other AIR survey populations.28
Moreover, it was shown that patients with achievement of
good control with inhaled corticosteroids were still vulner-
able to asthma exacerbations, usually in association with
clinical respiratory infections.29 Indeed, currently available
medications have been considered to fail to achieve
complete control of asthma in all patients even in the context
of clinical trials.30 Consistent with our findings, past studies
conducted in Turkey have also pointed out the inadequate
treatment of asthma as a common problem.15,31,32
Justifying recommendation of continuous preventive
care rather than symptom-driven and crisis oriented care in
several national and international ‘asthma management’
guidelines which place greater emphasis on the assessment
of asthma control versus asthma severity,11,33 our findings
related to higher costs including total direct cost, health-
care resource utilization, inpatient follow-up, asthma
medication, non-drug treatment, tests and consultations in
poor control of the disease are in line with the suggestion
concerning reduction in overall burden of the illness for
patients, healthcare systems, and society via achievement
of the optimal control of asthma.34
To assist with decisions on priorities and budgets for
healthcare, the present study presents national data oneconomic burden of asthma attacks in relation to clinical
presumptions regarding real-life management of asthma
disorder as well as acute asthma attack, retrospectively
from a Turkish perspective. This may provide a baseline
scale for future national studies concerning identification
of components of asthma cost across our country with
a special emphasis on “preventable” items which were
stated important for the development of successful cost
reduction strategies.35
In conclusion, since severe attack is associated with
increase in direct costs, health policies targeting achieve-
ment of better and stricter asthma control and lower disease
severity during the stable periods of the disease will play
a crucial role in the reduction of economic burden of asthma
for society and the patient. As drugs and hospitalization are
the principal components of the direct cost, appropriate
hospitalization of patients as well as rationale prescribing of
drugs seem to have a crucial role in the reduction of the
burden of asthma attacks on health economics.Acknowledgment
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